News

CADTH and Choosing Wisely Canada have convened a time-limited advisory panel to provide guidance on the minimum retesting intervals for 7 commonly used lab tests in Canada. Lab testing is a critical component of effective patient care and is a high-volume medical activity in Canada. The importance…
The field of complex care for children and youth is evolving, bringing forth new technologies and ways of providing care. A new CADTH report sheds light on the top technologies and issues that could shape the future of health care for children and youth with medical complexity.   Children and youth…
CADTH is seeking nominations for its expert and advisory committees. We are currently accepting applications from individuals with significant expertise working in various health care systems in Canada, who are interested in helping support health care decision-makers in making informed decisions…
On Rare Disease Day — a day when the international community raises awareness about rare conditions and their impact on patients’ lives — CADTH is announcing new work related to drugs for rare diseases.  In March 2023, the Government of Canada announced the National Strategy for Drugs for Rare…
We are pleased to announce that the 2024 Symposium Travel Awards Program is now accepting applications to support attendance by individuals who could not participate in the Symposium without financial support. Launched in 2007, the program is part of our commitment to making this important event…
We are thrilled to share that Suzanne McGurn, President and CEO, was presented with the Public Sector Leadership Award by the Canadian Organization for Rare Disorders (CORD). The award recognizes outstanding leadership and service as a public officer over multiple years across several agencies and…
Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review to identify process enhancements. We undertook this work as part of our commitment to continuous improvement and to advance our strategic ambitions to anticipate, innovate, and…
CADTH is working with a group of international health technology assessment (HTA) organizations to share learnings about the development of economic models that consider disease pathways. Globally, HTA organizations are seeing a growing number of drugs available for the same disease area. This can…
We are proud and excited to share that our organization has been named one of the National Capital Region's top employers for 2024. This special designation recognizes employers in the Ottawa-Gatineau area that lead their industries in offering exceptional places to work. We were measured against…
Current consultation status: Closed Consultation period: January 25 to February 22, 2024 CADTH is taking steps to help drug sponsors enhance the budget impact analyses (BIAs) included in the submissions they file with our Drug Reimbursement Review program. BIAs help decision-makers understand the…
Call for Nominations: Expert and Advisory Committee Members Coming Soon! The 2024 call for nominations will be open from March 4, 2024, to April 2, 2024. Please note the dates and length of the nominations window this year. CADTH recognizes that diversity of membership enhances its capacity for…
As announced on December 18 by the Government of Canada, CADTH will become the Canadian Drug Agency (CDA). We are excited and humbled by this opportunity. It builds on the trust we have established within the pan-Canadian drugs and devices environment, and our strong history of providing health…